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DOI 10.1186/s12879-015-0864-5RESEARCH ARTICLE Open AccessThe impact of anthelmintic treatment intervention
on malaria infection and anaemia in school and
preschool children in Magu district, Tanzania: an
open label randomised intervention trial
Safari M Kinung’hi1*, Pascal Magnussen2, Coleman Kishamawe1, Jim Todd3 and Birgitte J Vennervald2Abstract
Background: Some studies have suggested that helminth infections increase the risk of malaria infection and are
associated with increased number of malaria attacks and anaemia. Thus interventions to control helminth infections
may have an impact on incidence of clinical malaria and anaemia. The current study assessed the impact of two
anthelmintic treatment approaches on malaria infection and on anaemia in school and pre-school children in
Magu district, Tanzania.
Methods: A total of 765 children were enrolled into a prospective randomized anthelmintic intervention trial
following a baseline study of 1546 children. Enrolled children were randomized to receive either repeated
treatment with praziquantel and albendazole four times a year (intervention group, 394 children) or single dose
treatment with praziquantel and albendazole once a year (control group, 371 children). Follow up examinations
were conducted at 12 and 24 months after baseline to assess the impact of the intervention. Stool and urine
samples were collected and examined for schistosome and soil transmitted helminth infections. Blood samples
were also collected and examined for malaria parasites and haemoglobin concentrations. Monitoring of clinical
malaria attacks was performed at each school during the two years of the intervention.
Results: Out of 1546 children screened for P. falciparum, S. mansoni, S. haematobium, hookworm and T. Trichiura at
baseline, 1079 (69.8%) were infected with at least one of the four parasites. There was no significant difference in
malaria infection (prevalence, parasite density and frequency of malaria attacks) and in the prevalence of anaemia
between the repeated and single dose anthelmintic treatment groups at 12 and 24 months follow up (p > 0.05).
However, overall, there was significant improvement in mean haemoglobin concentrations (p < 0.001) from
baseline levels of 122.0g/L and 123.0g/L to 136.0g/L and 136.8g/L for the repeated and single dose treatment
groups, respectively, at 24 months follow-up which resulted in significant reduction in prevalence of anaemia.
Conclusions: These results suggest that repeated anthelmintic treatment did not have an impact on malaria
infection compared to single dose treatment. However, both treatment approaches had overall impact in terms
of improvements of haemoglobin levels and hence reductions in prevalence of anaemia.
Keywords: Anthelmintic intervention, Malaria infection, Anaemia, School children, Magu district* Correspondence: kinunghi_csm@hotmail.com
1National Institute for Medical Research (NIMR), Mwanza Centre, Isamilo
Road, PO Box 1462, Mwanza, Tanzania
Full list of author information is available at the end of the article
© 2015 Kinung'hi et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Kinung’hi et al. BMC Infectious Diseases  (2015) 15:136 Page 2 of 10Background
Malaria, schistosomiasis and soil transmitted helminth
infections (STH) are considered the most important
parasitic infections in Sub-Saharan Africa, contributing
to a major part of disease burden [1,2]. The diseases
share the same geographical distribution and occur as
co-infections in humans and thus interact with regards
to susceptibility, infection level, and pathology [3-5]. In
Tanzania, these infections occur throughout the country
and are a major public health problem particularly in
school and pre-school age children [5-8]. In school chil-
dren, the diseases are associated with impaired physical
and mental development, impaired learning capabilities,
undernutrition and anaemia [2,9,10].
Globally, major control interventions are currently
being undertaken to control malaria and helminth infec-
tions. These include use of insecticide impregnated bed
nets, indoor residual spraying (IRS) and early and effect-
ive detection and management of cases using artemisinin
based combination therapy for malaria [11-14]. For hel-
minth infections, control interventions include mass
drug administration using praziquantel and albendazole,
provision of safe water, improved sanitation and health
education [2,15].
Some previous studies have demonstrated that hel-
minth infections may increase the risk of infections with
P. falciparum [16-20] and other infections such as HIV
and TB [21,22]. However other studies have not found
this relationship [23]. Another important aspect of mal-
aria and helminth co-infections in humans is their joint
contribution to anaemia [24]. A study in Nepal [24] ob-
served that P. vivax malaria and hookworm co-infections
in pregnant women were associated with more fre-
quent malaria attacks and severe anaemia than seen in
women who harbour only one parasite infection. In the
Philippines, it was demonstrated that even at low in-
fection intensities, multiple parasite infections enhance
the risk of anaemia [25,26]. Thus interventions to con-
trol helminth infections in areas where helminth infec-
tions are co-endemic with malaria could be expected
to have not only an impact on prevalence and intensity
of helminth infections but also an impact on disease
burden due to malaria [27]. However there have been
few longitudinal randomized studies to test these hypo-
theses [28-30]. Most studies have been cross sectional in
nature and hence more longitudinal randomized studies
are needed.
The objective of this study was therefore to assess the
impact of an anthelmintic intervention delivered through
two different approaches on malaria infection and on
anaemia. The study was designed to test the hypothesis
that helminth infections modulate immune responses
against P. falciparum infection in an infection intensity
dependent manner and thus increase susceptibility tomalaria infection and related morbidity. Thus control of
helminth infections would enhance immune response
against P. falciparum malaria and reduce incidence of
clinical malaria attacks and anaemia.
Methods
Study area and population
The study was implemented in Magu district, Mwanza
region, North-western Tanzania, and involved six pri-
mary schools namely Mwamayombo, Nyashimo, Bulima,
Milambi, Ihale and Ijitu. From each school, school chil-
dren aged 6–13 years (grades I-V) were randomly selected
and included in the study. The aim was to get at least 100
children per school. Where the required number of 100
school children was not reached, pre-school children aged
3–5 years were also enrolled into the study. Selection of
pre-school children was made conveniently whereby par-
ents and guardians living in the community surrounding
each school were requested to bring their children to the
examination centre.
Study design, randomization and treatments
The study was a longitudinal open label intervention
trial which was preceded by cross-sectional baseline
study that enrolled 1546 children in the catchment areas
of the 6 primary schools. During the baseline study, the
prevalence and infection intensity of P. falciparum, S.
mansoni, S. haematobium, hookworm and T. trichiura
was determined using standard methods as described in
Kinung’hi et al. [5]. Haemoglobin concentrations were
also assessed using the Haemocue method. Quality control
was performed by re-examining 10% randomly selected
blood slides, urine filters and Kato smears by an experi-
enced independent technician.
Following the baseline study, 765 children were selec-
ted and included in the longitudinal study. The inclusion
criteria were: Being pre-school children (age 3 to 5 years)
or school children (age 6 to 13 years) living in the se-
lected villages for at least one year. In addition, selected
children were those infected with either S. mansoni or S.
haematobium or both. Exclusion criteria were: Children
who had stayed in the village for less than one year, chil-
dren whose parents or legal guardians did not provide
informed consent and children with severe malaria and
anaemia. Severe malaria was defined as a seriously sick
child presenting with fever (axillary temperature ≥ 37.5)
plus one or more signs of seizures, respiratory distress,
prostration, impaired consciousness or coma combined
with the presence of P. falciparum parasitemia but in
the absence of other causes of febrile illness [31,32]. Se-
vere anaemia was defined as a child with haemoglobin
concentrations below 80g/L. Children who had received
any anthelminthic treatment within one year before base-
line were also excluded from the study.
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variable for calculation of sample size. A minimum sample
size of 620 children (310 children for the repeated anthel-
mintic treatment group and 310 children for the single dose
treatment group) was considered sufficient to give a power
of 90% to be able to detect a significant difference of at least
5g/L between the two groups at 95% confidence interval
and 5% level of precision. However, after baseline survey
and assessment for inclusion criteria, 765 children were
selected and randomized into either the repeated anthel-
mintic treatment group (intervention group, 394 children)
or the single dose anthelmintic treatment group (control
group, 371 children). Generation of random allocation
sequence and assignment of participating children to inter-
vention and control groups was performed by an experi-
enced statistician.
Children in the intervention group were treated with
repeated doses of praziquantel 40mg/kg and albenda-
zole 400mg four times a year at three months interval
while children in the control group were treated with a
single dose of praziquantel 40mg/kg and albendazole
400mg once a year. The two treatment approaches for
the intervention and control groups were based on the
assumption that the intensive repeated treatment (four
times a year) of the intervention group will make this
group helminth free while for the control group, the
standard single dose treatment (once per year) will allow
for re-infection to take place in 50% or more of children
in this group [33-35]. Both praziquantel and albendazole
were supplied by the medical stores department of the
ministry of health and social welfare (MoHSW), Tanzania.
Treatments took place at the school premises and were
administered by a qualified medical doctor assisted by a
nurse and trained school teachers. Before taking the drugs,
children were given a piece of bread and a soft drink (fruit
juices) to minimise side effects of praziquantel. While
albendazole was given as a single dose at a dosage rate of
400mg, praziquantel was administered according to
weight. All drugs were taken orally together with clean
safe drinking water under direct observation. After taking
the drugs, children were allowed to rest for a period of
30–60 minutes during which side effects related to prazi-
quantel treatment were monitored. Overall praziquantel
was well tolerated except for mild abdominal discomforts
that lasted for about 30 minutes.
The cohort of 765 children was followed up at 12 and
24 months after baseline. During these two follow up time
points, the prevalence and infection intensity of P. falcip-
arum, S. mansoni, S. haematobium and hookworm as well
as haemoglobin concentrations were assessed. The
12 months follow up assessment took place between
October and November 2007 and included 655 children.
The 24 months follow up assessment took place between
October and November 2008 and involved 592 children. Ofthe 592 children who completed both the 12 months and
the 24 months surveys, 297 were from the intervention
group while 292 were from the control group. This
amounted to a compliance rate of 75.4% and 78.8%, re-
spectively. This study is registered on ClinicalTrials.gov,
registration number NCT00347113; registered June 30,
2006 and reported according to CONSORT guidelines for
randomized trials [36,37]. The study flow chart is shown in
Figure 1.
Major reasons for loss to follow-up included migration
from the study area, missing a second stool or urine sample,
withdrawal of consent, sickness during follow-up survey days
and death.
Monitoring of clinical malaria attacks
During the 24 months follow-up period, the incidence of
clinical malaria attacks was monitored at each primary
school assisted by trained school teachers. Monitoring of
incidence of clinical malaria attacks was done for all chil-
dren included in the longitudinal study by passive case de-
tection whereby children were asked to report to teachers
when they had febrile illness. The parents and guardians of
all children enrolled in this study were also informed about
the study and requested to report to teachers when their
children had febrile illness. The teachers were trained on
how to make presumptive diagnosis and treatment of mal-
aria cases. They were also trained to collect finger prick
blood, prepare and stain thick blood smears using the
Giemsa stain method and keep records. A register of mal-
aria cases was established at each primary school. A labora-
tory technician visited each school on a weekly basis to
collect the Giemsa stained blood smears and all informa-
tion recorded. Blood smear examination was undertaken at
the parasitology laboratory of the National Institute for
Medical Research (NIMR), Mwanza Centre. School children
found with febrile illness were treated with Artemether-
Lumefantrine which was the first line antimalarial drug at
the time of the study or were referred to nearby health facil-
ities according to national guidelines on malaria treatment.
A malaria episode (case) was defined as a child presenting
with febrile illness with axillary body temperature ≥37.5°C
plus a positive thick blood smear for malaria parasites in
the absence of signs for other infectious diseases.
Study outcomes
The following study outcome measures for malaria in-
fection and anaemia were assessed during the study:
 Prevalence of malaria parasitaemia defined as the
proportion of children with a positive blood smear
for malaria parasites by the Giemsa stain method.
 Malaria parasite density defined as the number of
malaria parasites per microlitre (μL) of blood
calculated assuming 8000 white blood cells/μL of
Figure 1 Study flow diagram.
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parasites per 200 leucocytes in Giemsa stained thick
films at 100× magnification. Malaria parasite density
was classified as low (<5000 parasites/μL of blood)
and high (≥5000 parasites/μL of blood).
 Incidence of clinical malaria attacks defined as
number of new cases of children presenting with
febrile illness with axillary body temperature ≥37.5°C
plus a positive thick blood smear for malaria
parasites by Giemsa stain method in the absence of
signs for other infectious diseases. The incidence of
clinical malaria attacks was observed for the entire
duration of the intervention (two years).
 Prevalence of anaemia and severe anaemia defined
as the proportion of children with haemoglobin
(Hb) concentrations less that 120 g/L and 80 g/L,
respectively, measured by the Haemocue method.Ethical statement
The study was approved by the Medical Research Co-
ordination Committee (MRCC) of the National Institute
for Medical Research (NIMR), Tanzania (Reference No.
NIMR/HQ/R.8a/Vol. IX/355). Before commencement of
the study, the research team conducted meetings with
village leaders, teachers and community members of all
selected villages. During these meetings, the objectives
and procedures of the study were explained including
study benefits and potential risks and discomforts. Writ-
ten informed consent for children who participated in
the study was sought from parents or legal guardians
after they had been informed about the study. Children
were also requested to give written assent and were in-
formed of their right to refuse to participate in the study
and to withdraw at any time during the study without
jeopardizing their right of access to other health services.
Table 1 Baseline characteristics of children included in
the trial by randomization group (n = 765)
Variable Intervention group
(n = 394)
Control group
(n = 371)
Sex
Boys (n = 392) 193 (49.0%) 180 (48.5%)
Girls (n = 373) 201 (51.0%) 191 (49.0%)
Age distribution (years)
3 – 5 (n = 93) 40 (10.1%) 53 (14.3%)
6 – 8 (n = 517) 278 (70.6%) 239 (64.4%)
9 – 13 (n = 155) 76 (19.3%) 79 (21.3%)
School
Mwamayombo 52 (51.5) 49 (48.5)
Nyashimo 85 (50.6) 83 (49.4)
Bulima 68 (50.7) 66 (49.3)
Milambi 56 (53.8) 48 (46.2)
Ihale 75 (51.4) 71 (48.6)
Ijitu 58 (51.8) 54 (48.2)
All schools 394 (51.5) 371(48.5)
S. mansoni infection
Prevalence (%) 238 (60.4) 220 (59.3)
Intensity (Epg)* 49 (42–59) 50 (42–59)
S. haematobium infection
Prevalence (%) 90 (22.8) 85 (22.9)
Intensity (Eggs/10 ml)* 15 (11–20) 17 (13–23)
S. mansoni/S. haematobium
co-infection
Prevalence (%) 65 (16.6) 61 (16.4)
S. mansoni intensity (Epg)* 31 (23–42) 41 (29–58)
S. haematobium intensity
(egg/10 ml)*
19 (11–28) 16 (10–26)
Malaria infection
Prevalence (%) 123 (31.2) 123 (33.2)
Parasite density (mps/μL)* 530 (414–676) 510 (403–644)
Hookworm infection
Prevalence (%) 80 (20.3) 68 (18.3)
Intensity (Epg)* 54 (39–76) 53 (39–73)
Prevalence of anaemia (%) 142 (36.7) 134 (35.5)
Prevalece of severe anaemia (%) 5 (1.3) 4 (1.1)
Mean haemoglobin level (g/L)** 122 (121–123) 123 (122–124)
Multiple infections (%)
Single parasite 199 (50.5) 186 (50.1)
Two parasites 148 (37.6) 136 (36.7)
Thee/four parasites 47 (12.0) 49 (13.2)
*Infection intensity expressed as geometric mean parasite counts of positive
samples only with 95% confidence interval shown in brackets.
**Mean haemoglobin concentrations with 95% confidence interval shown
in brackets.
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were explained to parents and children and were carried
out using sterile disposable materials. All children found
infected with any of the parasites S. mansoni, S. haema-
tobium, soil-transmitted helminthiasis and P. falciparum
and those found with ailments not targeted by the pro-
ject were treated free of charge according to national
guidelines. Study identification numbers were used in-
stead of children names and information collected was
kept confidential. Feedback to the study population in
the form of dissemination workshops was conducted
during the course of the study.
Data management and statistical analysis
Data were double entered into Dbase V software (Borland
International, Scotts Valley, California, USA) and analyzed
using STATA Version 10 (STATA Corp., Texas, USA).
Infection intensities (of positive samples only) were
calculated as geometric mean of parasites per microlitre
of blood for P. falciparum and geometric mean of eggs
per gram of faeces for S. mansoni and hookworms. For
S. haematobium, infection intensity was calculated as
geometric mean of eggs per 10ml of urine. For each
survey point (baseline, 12 months follow up and 24
months follow up), the Chi-square test was used to
compare proportions (prevalence) of malaria infection
and prevalence of anaemia between the intervention
and control groups. Likewise, for each survey point, the
student’s t-test was used to compare geometric mean
parasite counts and mean haemoglobin concentrations
between the intervention and control groups where
two groups were compared. The repeated measures ana-
lysis of variance (rmANOVA) was used to compare geo-
metric mean parasite counts and mean haemoglobin
concentrations where repeated measurements for all three
survey points (baseline, 12 months follow up and 24
months follow up) were compared longitudinally. Com-
parison of the incidence (or risk) of clinical malaria attack
among children in the intervention group and those in the
control group was performed by calculating the relative
risk (risk ratio) using 2×2 contingency tables. Tests were
considered statistically significant at p < 0.05.
Results
Baseline characteristics
Table 1 shows baseline characteristics of children in-
cluded in the longitudinal study. There were no signifi-
cant differences in baseline characteristics of children in
the two groups.
Out of the 765 children included in the longitudinal
study, 589 (77.0%) completed the two year follow up
period and were included in the analysis of whom 291
(49.4%) were boys. Mean age was 9 years. Out of the 589
children who completed the 24 months follow up, 302
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P. falciparum, S. mansoni, S. haematobium, Hookworm
and T. trichiura. Children who were infected with P.
falciparum were 144 (24.5%), out of whom 55 (38.2%)
had helminth co-infections. Only 3 children (0.5%) had
T. Trichiura infection and hence T. Trichiura infection
was excluded from further analysis.
Effect of the intervention on malaria infection,
haemoglobin concentrations and anaemia
There was no significant difference in malaria infec-
tion (prevalence and malaria parasite density) and in
the prevalence of anaemia between the intervention
and control groups at 12 and 24 months follow up
period (p > 0.05) (Table 2). However, overall, there was
a significant improvement in mean haemoglobin con-
centrations (F = 96.47, p < 0.001) from baseline levels of
122.0g/L (95% CI 120.5-123.4) and 123.0g/L (95% CI
121.6-124.5), for the intervention and control groups,
respectively, to 136.0g/L (95% CI 134.2-137.8) and
136.8g/L (95% CI 135.0-137.7) for the intervention and
control groups, respectively, at the 24 months follow-up
period which resulted in a significant reduction in the
prevalence of anaemia over the two years period but
without significant differences between intervention and
control groups (Table 2).Table 2 Comparison of overall prevalence and geometric mea
and anaemia after one and two years of anthelmintic treatme
Variable/randomization group Baseline
Prevalence of P. falciparum infection (n,%)
Intervention 123 (33.2)
Control 123 (31.2)
p-value 0.567
Intensity of P. falciparum infection (95% CI)
Intervention 530 (414-678)
Control 510 (403-645)
p-value 0.825
Prevalence of anaemia (n,%)
Intervention 142 (36.0)
Control 134 (36.1)
p-value 0.971
Prevalence of severe anaemia (n,%)
Intervention 5 (1.3)
Control 4 (1.1)
p-value NA
Mean haemoglobin level in g/L (95% CI)
Intervention 122.0 (120.5-123.4)
Control 123.0 (121.6-124.5)
p-value 0.270Baseline prevalence of heavy P. falciparum infection
(≥5000 mps/μL) was 2.1% and 2.2% for the intervention
and control group, respectively and was reduced to 0%
at the end of the intervention. This represented a signifi-
cant reduction over the two years follow up period but
without significant differences between groups (χ2 = 0.07,
p = 0.790). Likewise, there was an overall significant reduc-
tion in malaria parasite density (F = 32.94, p < 0.001) from
baseline levels of 530 (95% CI 414–678) and 510 (95% CI
403–645), for the intervention and control groups, re-
spectively, to 326 (95% CI 279–382) and 343 (95% CI
294–400) for the intervention and control groups, respect-
ively, at the 24 months follow-up period but without sig-
nificant differences between groups (t = 0.44, p = 0.658)
(Table 2). However, for all groups, there was an increase
in malaria prevalence and malaria parasite density from
baseline to 12 months follow up (Table 2) which could be
a result of other factors such as climate variability and sea-
sonality of malaria transmission.
Incidence of clinical malaria cases
Out of the 765 children originally included in the longi-
tudinal follow up, 589 (77.0%) children completed the
two year follow up period for malaria attacks (297 were
in the intervention group while 292 were in the control
group). A total of 221 children presented with febrilen parasite density of malaria infection, mean Hb levels
nt by randomization groups
12 months follow up 24 months follow up
145 (44.9) 74 (24.9)
137 (42.4) 70 (24.0)
0.526 0.790
833 (664-1048) 326 (279-382)
906 (724-1133) 343 (294-400)
0.608 0.658
120 (37.2) 43 (14.5)
112 (34.7) 38 (13.0)
0.806 0.634
1 (0.3) -
1 (0.3) -
NA NA
123.5 (121.9-125.0) 136.0 (134.2-137.8)
123.2 (121.7-124.6) 136.8 (135.0-137.7)
0.749 0.494
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intervention group and 107 were from the control
group. However only 85 children (38.5%) met the cri-
teria of confirmed malaria cases (axillary temp ≥37.5%
plus a blood smear positive for malaria parasites). Forty
confirmed malaria cases were reported from the interven-
tion group while 45 confirmed malaria cases were repor-
ted from the control group. Eighteen children (21.2%)
reported more than one episode of clinical malaria attacks
(2–4) per year during the first year of the intervention.
However, this occurred less frequently during the second
year of the intervention whereby only 7 children (8.2%)
reported more than one episode of clinical malaria attacks
with the highest frequency of 2 attacks per child per year.
There was clustering of overall clinical malaria attacks by
school which corresponded with baseline malaria preva-
lence at respective schools (data not shown).
Overall, there was no significant differences in the
incidence of clinical malaria attacks (RR = 1.144, 95%
CI 0.759-1.725, p = 0.519) or malaria parasite density
(t = −0.76, p = 451) between children in the intervention
group and those in the control group (Table 3).
Discussion
Results of the current study suggest that repeated an-
thelmintic treatment (treatment with praziquantel and
albendazole four times a year) did not have any impact
on malaria infection (prevalence, malaria parasite density
and frequency of malaria attacks) compared to the single
dose annual treatment as no differences were observed
between children in the repeated anthelmintic treatment
(intervention) group compared to children in single dose
annual treatment (control) group. This is contrary to
what was expected. Previous studies had observed that
helminth infections increases the risk of malaria infection
[17-19,38,39] which could imply that an anthelmintic
treatment intervention would result in reduced frequency
of malaria attacks and/or malaria parasite densities in
areas where both malaria and helminth infections are co-
endemic [40]. One explanation of this finding could be
that the impact of helminth infections on malaria infec-
tion is intensity dependent such that heavy helminth in-
fections are required to induce a shift in Th1/Th2 balance
which in turn would be reflected in differences in the
observed malaria infection between children in theTable 3 Malaria case incidence and malaria parasite density b
Variable Intervention group (n = 297)
Malaria case incidence* 6.7 (4.8-8.9)
Malaria parasite density** 2658 (1647-4291)
*Malaria case incidence defined as the number of new clinical malaria attacks obse
intervals shown in brackets.
**Malaria parasite density expressed as geometric mean malaria parasites per micro
shown in brackets.intervention and control groups. This view is supported
by findings of Sokhna et al. [18], Fenton [41] and Wiria
et al. [42]. Sokhna et al. [18] observed that the incidence
rate of malaria attacks was significantly higher in Senegalese
children infected with S. mansoni particularly those
carrying the highest egg loads as compared to uninfected
children. Fenton [41] observed that the outcomes of coin-
fection are highly dependent on helminth burden among
other factors. Another recent study by Waknine-Grinber
et al. [43] demonstrated that concomitant S. mansoni in-
fection reduced the incidence of cerebral malaria in P.
bergheii infected mice but the effect was dependent on S.
mansoni parasite load. As most of the helminth infections
in this study were light, their impact on malaraia infec-
tions might have been weak. The results are however in
agreement with findings of Beasley et al. [44] who worked
with school children aged 7–12 years in Tanga Region in
Northeast Tanzania where malaria, S. haematobium and
STHs are co-endemic. He observed that 15 to 16 weeks
following anthelmintic treatment using praziquantel and
albendazole, children in the treatment group had signi-
ficant reductions in prevalence and infection intensity of
S. haematobium and STHs and in the prevalence of
anaemia compared to children in the control (placebo)
group but did not differ in terms of prevalence and infec-
tion intensity of P. falciparum malaria. Another important
observation was the relatively few confirmed malaria at-
tacks relative to the number of cases who reported with
febrile illness. Out of the 221 reported cases of febrile
illness, only 85 (38.5%) were confirmed to be due to
P. falciparum infection. This observation suggests that
there are other causes of febrile illness in this study
area. Similar observations have been made in other parts
of Tanzania [45-47] and hence there is a need for further
longitudinal studies.
As observed by previous studies investigating the asso-
ciation between malaria and helminth infections [23,48],
one weakness of the design of the current study is the
lack of a proper untreated control group due to ethical
reasons. While children in the intervention group were
treated with praziquantel 40mg/kg and albendazole
400mg four times a year, children in the comparison group
had to be treated using the minimum recommended
single dose of praziquantel 40mg/kg and albendazole
400mg annually according to the national schistosomiasisy treatment group over 24 months follow up period
Control group (n = 292) P-value
7.7 (5.7-10.1) 0.519
3100 (1831-5249) 0.451
rved in a given treatment group per 100 person years with 95% confidence
litre of blood (mps/μL) (positive samples only) with 95% confidence intervals
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Tanzania. Although it was assumed that the single dose
annual anthelminthic treatment of children in the control
group would allow for re-infection of 50% or more of
children in this group and that this level of helminth
re-infection would still induce the same effect on malaria
infection, the treatment might have contributed to lack of
differences in malaria infection between children in the
intervention group compared to those in the control group.
Despite the lack of significant differences between the
study groups, there was an overall reduction in prevalence
of malaria parasitaemia, intensity of infection and number
of malaria attacks from baseline through to the 12 months
and 24 months follow up surveys. However, this reduction
was not consistent over time since the prevalence and in-
fection intensity of malaria infection was higher at the first
(12 months) follow up survey. The fact that this reduction
was not consistent over time suggests that other factors
such as seasonal variation in malaria transmission resulting
from malaria vector dynamics and climatic/environmental
factors might have acted as confounding factors and con-
tributed to the overall reduction observed.
Earlier studies to investigate the association between
malaria and helminth infections using a randomized de-
sign include the study of Murray et al. [49] which sugges-
ted that treatment of children with helminth infections
(A. lumbricoides) resulted into an increase of malaria cases.
Two further studies with similar design were conducted in
Madagascar [50,51] and showed that children aged more
than 5 years treated for helminths (A. lumbricoides) had a
significant increase in malaria parasite densities compared
to untreated controls suggesting a negative interaction
between A. lumbricoides infection and malaria parasite
density. It might be difficult to compare findings of the
current study with the studies of Murray and Brutus.
While the study of Murray et al. [49] included a very
small sample size (only 35 children were studied), all
the three studies [49-51] investigated the association
between P. falciparum and A. lumbricoides infections
which involved a different helminth specie (A. lumbri-
coides) from the helminth species investigated in the
current study (S. mansoni, S. haematobium and hook-
worms). Further, the studies of Murray and Brutus were
conducted in a different epidemiological setting (and
hence different disease transmission patterns) and used
different treatment regimen against helminth infections.
While Murray et al. [49] used piperazine to treat STH
infections, Brutus et al. [50,51] used levamisole to treat
STH infections. No treatment was given against schisto-
some infections.
Likewise, there were no significant differences in
prevalence of anaemia or in haemoglobin levels between
children in the intervention group compared to children in
the control group over the two years assessment periods.However, for both groups, there was significant improve-
ment in mean haemoglobin levels and hence a reduction
in prevalence of anaemia. The observed changes in
haemoglobin levels and the prevalence of anaemia
followed a similar trend as changes in the prevalence and
infection intensity of malaria suggesting that malaria in-
fection was the most important contributor to anaemia in
the studied population in line with findings of other stud-
ies [52,53]. Further, the anthelmintic intervention might
have contributed to the improvement in haemoglobin
levels and hence reduction in the prevalence of anaemia
by acting through reductions in prevalence and infection
intensity of helminth infections (S. mansoni, S. haemato-
bium and hookworms) and the prevalence and infection
intensity of P. falciparum infection in line with reports by
other investigators [27,44,54,55]. This argument is suppor-
ted by baseline findings [5] whereby multivariate analysis
showed that P. falciparum and S. haematobium infections
were the most important predictors of anaemia in the
studied population. Other studies which have provided
evidence on the importance of malaria infections on an-
aemia include studies on interventions directed against
malaria such as Insecticide Treated Nets (ITNs) and
chemoprophylaxis. Results of these studies demonstrated
increases in haemoglobin levels and a strong impact on
anaemia [56,57]. The most striking impact of the anthel-
mintic intervention was on severe anaemia which was
reduced by 100% for both the intervention and control
groups.
Conclusions
In conclusion, findings of the current study show that
repeated anthelmintic treatment did not have a direct
impact on malaria infection (prevalence, malaria parasite
density and frequency of malaria attacks) as compared
to single dose annual treatment. However, both treat-
ments had an overall impact in terms of improvements
of haemoglobin levels and hence reductions in preva-
lence of anaemia.
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